How GLP-1 Receptor Agonists Work in Type 2 Diabetes
To understand why these medications are so effective, it helps to understand the biology of GLP-1 itself. Glucagon-like peptide-1 is an incretin hormone secreted by the gut in response to food intake. It performs several critical functions: it stimulates insulin secretion from the pancreas in a glucose-dependent manner, suppresses glucagon release from alpha cells, slows gastric emptying, and promotes satiety.
In people with type 2 diabetes, the incretin effect is blunted — the gut does not release enough GLP-1 in response to meals, and the pancreas does not respond adequately to whatever GLP-1 is present. GLP-1 receptor agonists solve this problem by flooding the receptor sites with a pharmacologic version of the hormone, restoring the incretin effect even when the body's own GLP-1 production is impaired.
Critically, because the insulin secretion is glucose-dependent, the risk of hypoglycemia is substantially lower with GLP-1 receptor agonists than with sulfonylureas or insulin. When blood glucose is already normal or low, the GLP-1 signal does not stimulate additional insulin release. This built-in safety mechanism makes these medications easier to use, especially in older patients or those with irregular eating patterns.
HbA1c Reduction: What to Expect
Clinical trials consistently show that GLP-1 receptor agonists produce meaningful reductions in HbA1c — the measure of average blood glucose over the preceding 2-3 months. The magnitude of reduction depends on the specific medication, the dose, and the patient's baseline HbA1c.
Semaglutide, particularly the injectable formulation at higher doses, produces average HbA1c reductions of 1.5-2.0 percentage points. Tirzepatide, which acts on both GLP-1 and GIP receptors, produces even larger reductions — in the range of 2.0-2.5 percentage points on average, with some patients achieving reductions exceeding 3 percentage points.
For context, the American Diabetes Association recommends an HbA1c target of below 7% for most adults with diabetes, and more stringent targets of 6.5% or lower for many younger, healthier patients. Many patients on GLP-1 receptor agonists achieve these targets, particularly when the medication is combined with metformin or other background therapies.
